NCT07128186 · RECRUITING

The Application of an AI-driven Multimodal Predictive Model for Cognitive Impairment in Patients With Type 2 Diabetes Mellitus

This observational study is testing whether an AI-powered screening tool can detect early memory and thinking problems in people who have type 2 diabetes. Researchers will follow participants for 3 to 5 years, tracking blood sugar control alongside cognitive changes. There is no drug or treatment involved — just monitoring and testing. The phase is unspecified, meaning this is likely a feasibility or validation study, not a clinical treatment trial.

Eligibility criteria

Inclusion Criteria:
Inclusion Criteria
1. Diagnosed with type 2 diabetes mellitus (T2DM).
2. Aged 40-75 years, with self-reported or informant-reported memory complaints.
3. Cognitive assessment scores consistent with either:
   * Cognitive Normal (CN) or
   * Mild Cognitive Impairment (MCI).
4. Preserved ability to perform basic activities of daily living (ADLs).
5. Memory-specific deficits only (e.g., partial forgetfulness), with intact other cognitive domains (e.g., reasoning, judgment, attention, and executive function).
Exclusion Criteria:
1. Other types of diabetes (e.g., type 1 diabetes, gestational diabetes).
2. Education level \<6 years.
3. Metabolic disorders that may affect cognition, including:
   * Acute carbohydrate metabolism events within 3 months (e.g., severe hypoglycemia, diabetic ketoacidosis, hyperglycemic hyperosmolar state).
   * Hypothyroidism or other endocrine disorders.
4. Neurological/psychiatric conditions that may impair cognition:
   * History of head trauma, depression, anxiety, delirium, severe pulmonary/renal disease, heart failure, or malignancy.
5. Substance abuse (past 2 years), including nicotine/alcohol dependence.
6. Recent medication use (within 1 month):
   * Anti-Parkinsonian drugs, antiepileptics, sedatives/hypnotics.
7. Cognitive-enhancing drugs (e.g., donepezil, memantine).
8. Inability to complete AI screening or follow-up due to:
   * Speech/hearing/visual impairments or other disabilities

The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.

Eligibility criteria as of 2025-08-17

View full record on ClinicalTrials.gov

All APOE4 clinical trials